Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| LCE#40378 | Other Identifier | Merck |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback to the general practitioner, can improve metabolic control and overall cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM), as compared to usual practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telemedicine system | Experimental | Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits. |
|
| Usual care | No Intervention | Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Home telehealth system | Device | Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in blood glucose level | Baseline and 12 months | |
| Change from baseline in blood pressure | Baseline and 12 months | |
| Change from baseline in body mass index | Baseline and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants who achieved hemoglobin A1c (HbA1c) <7.0% | Up to 12 months | |
| Percentage of participants who achieved blood pressure <130/80 mmHg | Up to 12 months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26154338 | Derived | Nicolucci A, Cercone S, Chiriatti A, Muscas F, Gensini G. A Randomized Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Patients with Type 2 Diabetes. Diabetes Technol Ther. 2015 Aug;17(8):563-70. doi: 10.1089/dia.2014.0355. Epub 2015 Jul 8. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage of participants who achieved low-density lipoprotein (LDL) cholesterol <100 mg/dL |
| Up to 12 months |
| Percentage of participants requiring therapy modifications | Up to 12 months |
| Change from baseline in total cholesterol | Baseline, 6 months, and 12 months |
| Change from baseline in high-density lipoprotein (HDL) cholesterol | Baseline, 6 months, and 12 months |
| Change from baseline in LDL cholesterol | Baseline, 6 months, and 12 months |
| Change from baseline in triglycerides | Baseline, 6 months, and 12 months |
| Change from baseline in cardiovascular risk score | Baseline, 6 months, and 12 months |
| Number of emergency room visits and hospital admissions | Up to 12 months |
| Number of office visits and home visits | Up to 12 months |
| Change from baseline in the number and doses of drugs for treatment of diabetes | Baseline and 12 months |
| Change from baseline in the number and doses of drugs for treatment of hypertension | Baseline and 12 months |
| Change from baseline in the number and doses of drugs for treatment of dyslipidemia | Baseline and 12 months |
| Participant overall satisfaction level | Up to 12 months |
| Participant compliance with protocol-provided devices | Up to 12 months |
| Number of participants who experienced hypoglycemia | Up to 12 months |
| Number of hypoglycemic episodes | Up to 12 months |
| Number of participants who experienced severe/symptomatic hypoglycemia | Up to 12 months |
| Number of severe/symptomatic hypoglycemic episodes | Up to 12 months |
| D004700 | Endocrine System Diseases |